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a b s t r a c t
Japanese encephalitis virus is one of the most common causes for epidemic viral encephalitis in humans
and animals. Herein we demonstrated that cellular helicase DDX3 is involved in JEV replication. DDX3
knockdown inhibits JEV replication. The helicase activity of DDX3 is crucial for JEV replication.
GST-pulldown and co-immunoprecipitation experiments demonstrated that DDX3 could interact with
JEV non-structural proteins 3 and 5. Co-immunoprecipitation and confocal microscopy analysis
conﬁrmed that DDX3 interacts and colocalizes with these viral proteins and viral RNA during the
infection. We determined that DDX3 binds to JEV 5′ and 3′ un-translated regions. We used a JEV-replicon
system to demonstrate that DDX3 positively regulates viral RNA translation, which might affect viral RNA
replication at the late stage of virus infection. Collectively, we identiﬁed that DDX3 is necessary for JEV
infection, suggesting that DDX3 might be a novel target to design new antiviral agents against JEV or
other ﬂavivirus infections.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Japanese encephalitis virus (JEV), a mosquito-borne ﬂavivirus,
is one of the most common causes for epidemic viral encephalitis
in humans and animals (Solomon, 2003; Tsai, 2000). Its genome
encodes a single polyprotein composed of three structural proteins
[core, membrane (prM/M), and envelope (E)] and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5). The mature viral proteins are produced via proteolytic
processing of the single polyprotein by viral serine protease
(NS2B-NS3) and cellular proteases (Lindenbach and Rice, 2001,
2003). The viral replication is initiated by the replication complex
through a process of RNA-dependent RNA polymerization in the
perinuclear endoplasmic reticulum membranes (Westaway et al.,
2003). Nonstructural proteins 3 and 5 are components of the
replication complex, which associates with the 3′ noncoding
region of genomic RNA to initiate viral replication (Chen et al.,
1997; Edward and Takegami, 1993). NS5, the largest and most
conserved viral protein, contains methyltransferase (MTase) and
RNA-dependent RNA polymerase (RdRp) domain. The MTase is
involved in methylation of the 5′-cap structure of genomic RNA,
while RdRp is important for viral genome replication (Ackermann
and Padmanabhan, 2001; Egloff et al., 2002; Guyatt et al., 2001;
Koonin, 1993). Until now there is no speciﬁc and effective treat-
ment available for Japanese encephalitis virus infection; vaccina-
tion is the only effective control measure. Although vaccination is
widely used, some public health concerns exist (Takahashi et al.,
2000).
Cellular DEAD-box helicases reside in both nucleus and cyto-
plasm (Chao et al., 2006; Yedavalli et al., 2004); they are involved
in a variety of cellular processes related to RNA, such as splicing,
mRNA export, transcriptional and translational regulation, RNA
decay and ribosome biogenesis(Beckham et al., 2008; Choi and
Lee, 2012; Garbelli et al., 2011; Rocak and Linder, 2004; Shih et al.,
2007; Soulat et al., 2008). DDX3(X), identiﬁed in 1997, is a member
of the DEAD (Asp–Glu–Ala–Asp)-box helicase family (Park et al.,
1998). It is ubiquitously expressed in a wide range of tissues (Kim
et al., 2001). DDX3 has orthologous candidates in many eukar-
yotic organisms from yeast and plants to animals; they share
signiﬁcant identities between each other (Garbelli et al., 2011).
DDX3 is a nucleo-cytoplasmic shuttling protein characterized by
nine conserved motifs. It displays RNA-dependent ATPase and
ATP-dependent RNA helicase activities (Rocak and Linder, 2004;
Schröder, 2010).
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Recently, DDX3 attracts great interest because several studies
have shown that it is involved in the replication of several viruses
that have major global health threats, such as Human Immuno-
deﬁciency Virus (HIV) (Owsianka and Patel, 1999), Hepatitis B
Virus (Wang et al., 2009), Hepatitis C virus (HCV) (Ariumi et al.,
2007; Mamiya and Worman, 1999; Owsianka and Patel, 1999; You
et al., 1999) and poxviruses (Kalverda et al., 2009). The other
cellular helicases such as DDX1, DDX5, DHX15, DDX28, DDX56 and
DDX42 are the cofactors for the replication of HIV, coronavirus,
hepatitis B virus, HCV, JEV and WNV (Ariumi et al., 2007; Fang
et al., 2005, 2004; Li et al., 2013; Wang et al., 2009; Xu et al., 2010,
2011; Xu and Hobman, 2012). Two recently published papers
report that the novel DDX3 inhibitors possess the anti-HIV activity
which highlights DDX3 as a novel target for the development of
antiviral agents (Maga et al., 2011; Radi et al., 2012).
In order to determine whether DDX3 is involved in the JEV
infection, we ﬁrst silenced the endogenous DDX3 expression and
found that JEV replication was signiﬁcantly reduced. We then
determined that the helicase activity is crucial for JEV replication
by studying the effects of the helicase-dead DDX3 mutants and
DDX3 inhibitor on virus replication. Furthermore, we also demon-
strated that DDX3 could interact with JEV NS3, NS5-MTase and
NS5-RdRp proteins. Meanwhile, we found that DDX3 could bind to
the JEV 5′ and 3′ un-translated regions (UTR) and colocalize with
viral RNA during viral infection. Finally, we showed that DDX3
plays an important role in viral protein translation, which might
affect the viral RNA replication at the late stage of viral infection.
Collectively, our studies demonstrated that cellular DDX3 plays
critical roles in regulating JEV infection.
Results
Requirement of endogenous DDX3 for JEV replication
It has been reported that DDX3 plays important roles in the
replication of several viruses (Garbelli et al., 2011; Schröder, 2010).
To determine whether DDX3 is required for JEV replication, we
Fig. 1. Requirement of DDX3 for JEV replication. (A) Western blotting analysis of cellular lysate using anti-DDX3 or anti-β-actin antibody after DDX3 knockdown by DDX3
shRNA. (B) Viral titers determined by plaque formation assay after DDX3 knockdown. BHK-21 cells transfected with the DDX3 shRNA were infected with JEV (MOI¼0.01) for
48 h, Viral titers determined by plaque formation assay at 48 hpi. (C) The JEV genomic RNA levels in JEV infected BHK-21 cells monitored by Q-PCR after DDX3 knockdown.
BHK-21 cells transfected with the DDX3 shRNA were infected with JEV (MOI¼0.01) for 48 h, JEV RNA copy number was determined by Q-PCR at 48 hpi. (D) Western blot
analysis on the JEV envelope (E protein) and NS5 protein expression levels in JEV infected BHK-21 cells after DDX3 knockdown. (E) BHK-21 cells transfected with the DDX3
shRNA were infected with JEV (MOI¼0.01) for 48 h. The amount of virus released into the medium was determined by plaque formation assay at different time points.
(F) BHK-21 cells transfected with different amounts of DDX3 shRNA plasmid were infected with JEV (MOI¼0.01), 48 h later, the amount of virus released into the medium
was determined by plaque formation assay. The differences between means were considered signiﬁcant at *po0.05, very signiﬁcant ** po0.01.
C. Li et al. / Virology 449 (2014) 70–81 71
ﬁrst used DDX3 shRNA to reduce the expression level of endogen-
ous DDX3 before the cells were infected with JEV (MOI¼0.01).
Western blot analysis using anti-DDX3 antibody demonstrated
that 90% reduction of protein expression level was achieved upon
gene silencing compared with the control (Fig. 1A). A reduction of
the endogenous DDX3 expression resulted in more than 15-fold
decrease in viral titers (Fig. 1B) and a signiﬁcant decrease in JEV
genomic RNA level (Fig. 1C). The viral protein expression level was
also decreased after DDX3 silencing as detected by Western blot
analysis using anti-JEV-envelope monoclonal antibody and anti-
JEV-NS5 polyclonal antibody (Fig. 1D).
As knockdown of DDX3 can inﬂuence the replication of JEV at
48 hpi, we further determined the effect of knockdown of DDX3
on JEV replication at different time points. The cells were infected
with JEV (MOI¼0.01) after being transfected with DDX3 shRNA
plasmid; the virus loads were determined at different time points.
As shown in Fig. 1E, the titers of JEV in DDX3 knockdown cells
were lower than that in the control cells (po0.01). At the same
time, we determined whether the effect of DDX3 knockdown on
JEV replication is dose-dependent; we transfected the BHK-21 cells
with different amounts of DDX3 shRNA plasmid before infecting
the cells with JEV (MOI¼0.01). The virus load analysis showed that
DDX3 knockdown reduced JEV titers in a dose-dependent manner.
The DDX3 shRNA interference efﬁciency of different amounts of
DDX3 shRNA plasmid was detected using anti-DDX3 polyclonal
antibody (Fig. 1F).
DDX3 knockdown does not affect JEV assembly or release
In order to determine whether cellular DDX3 is involved in
virus assembly or release, the BHK-21 cells were transfected with
DDX3 shRNA plasmid before being infected with JEV (MOI¼0.01).
48 h later, the JEV RNA copy numbers between the supernatants
and the cell lysates were detected; although the RNA copy
numbers in the cell lysates were nearly 15-fold higher than that
in the supernatants, the ratios between them were almost the
same between the DDX3 knockdown cells and the control cells
(p40.05), demonstrating that DDX3 silencing did not affect JEV
assembly (Fig. 2A). Meanwhile, the ratios of the viral titers in the
supernatants and cell lysates were also similar between DDX3
knockdown cells and the control cells (p40.05) as determined by
plaque formation assay (p40.05) (Fig. 2B), indicating that DDX3
knockdown did not affect the virus release.
The helicase activity of DDX3 is crucial for JEV infection
In order to determine whether the helicase activity of DDX3
was important for JEV replication, the DDX3 helicase-dead mutant
lacking either ATPase activity (K230E) or RNA unwinding activity
(S382L) (Cordin et al., 2006; Garbelli et al., 2011) was used. BHK-21
cells were ﬁrst transfected with DDX3 shRNA plasmid to decrease
the endogenous DDX3 expression level. 24 h later, the cells were
transfected with RNA interference-resistant plasmid (to exclude
the inﬂuence of DDX3 shRNA plasmid) pCDNA3.1-DDX3r-HA,
pCDNA3.1-DDX3r-K230E-HA or pCDNA3.1-DDX3r –S382L-HA before
the cells were infected with JEV (MOI¼0.01). The virus titers were
detected 2 days later by plaque formation assay, the results
showed that overexpression of DDX3r-K230E, DDX3r-S382L and
the control plasmid pcDNA3.1 after DDX3 knockdown resulted in
the reduction of JEV replication for 13-fold (po0.01), 12-fold
(po0.01) and 15-fold (po0.01). Meanwhile overexpression of
DDX3r after DDX3 knockdown did not reduce JEV replication
when compared with the control cells (Fig. 3A), suggesting that
overexpression of the exogenous DDX3r could restore JEV replica-
tion. The Q-PCR results of the DDX3r, DDX3r-K230E or DDX3r-
S382L transfected cells after DDX3 knockdown were consistent
with the results of plaque formation assay (Fig. 3B) (po0.01). The
expression of endogenous DDX3 or DDX3 mutants was conﬁrmed
by Western blot analysis using anti-HA monoclonal antibody and
anti-DDX3 polyclonal antibody (Fig. 3C). Both of the results
demonstrated that DDX3 helicase activity was crucial for JEV
infection. The cell viability of all DDX3 constructs and control
plasmids transfected BHK-21 cells was not signiﬁcantly affected as
determined by using the cytotoxicity test using CytoTox 96s
NonRadioactive Cytotoxicity Assay Kit (Fig. 3D).
It has been shown that DDX3 is involved in HIV-1 replication by
exporting un-spliced or partially spliced viral RNAs from the
nucleus to the cytoplasm (Yedavalli et al., 2004), and one recently
published paper reported that two chemical compounds (Cmp6
and Cmp8) can speciﬁcally inhibit the helicase activity of DDX3,
and therefore inhibit HIV replication in PBMCs (Radi et al., 2012).
We synthesized Cmp6 to further conﬁrm whether DDX3 helicase
activity is critical for JEV infection. We infected BHK-21 cells with
JEV virus (MOI¼0.01) at 37 1C for 2 h before Cmp6 was added
(0–50 μM). The plaque formation assay at 48 hpi showed that
Cmp6 signiﬁcantly inhibited JEV replication by 20-fold at the
concentration of 50 μM (Fig. 4A). The Q-PCR also conﬁrmed the
results (Fig. 4B), and the results were consistent with the DDX3
helicase-dead mutants experiment. Meanwhile, we conﬁrmed that
Cmp6 did not stimulate signiﬁcant cytotoxicity in BHK-21 cells at
the concentration of 50 μM, while signiﬁcant cytotoxicity was
detected at the concentration of 100 or 200 μM by LDH assay
(Fig. 4C). Therefore, 0–50 μM of Cmp6 was used in our study. In
summary, our results suggested that the helicase activity of DDX3
was necessary for JEV infection.
Fig. 2. The effects of DDX3 knockdown on JEV assembly and release. (A) The
inﬂuence of DDX3 knockdown on virus assembly. The ratio of JEV RNA copy
numbers between the supernatants and the cell lysates were detected by Q-PCR at
48 hpi. (B) The inﬂuence of DDX3 knockdown on virus release. The BHK-21 cells
was infected with JEV (MOI¼0.01) after DDX3 silence, the ratio of the virus titers in
supernatants and cell lysates were determined by plaque formation assay at 48 hpi.
The differences between means were considered signiﬁcant at *po0.05, very
signiﬁcant **po0.01.
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DDX3 can interact with JEV NS3 and NS5 proteins
It has also been shown that both JEV NS3 and NS5 are compo-
nents of the replication complex (Uchil and Satchidanandam, 2003).
We next determined whether DDX3 was involved in JEV replication
by interacting with JEV proteins responsible for viral RNA replication.
We used GST-pulldown assay to monitor the interactions between
NS3, NS5-MTase, NS5-RdRp and DDX3 or vice versa. The Western
blot analysis showed GST-NS3, GST-NS5-MTase or GST-NS5-RdRp
could interact with DDX3 (Fig. 5A), and GST-DDX3 could also interact
with His-tagged JEV NS3, NS5-Mtase or NS5-RdRp (Fig. 5B).
NS5 and NS3 has been hypothesized to seed the formation of
the replication complex, and they may form a replication complex
together with 3′ noncoding region of JEV genomic RNA (Uchil and
Satchidanandam, 2003). Therefore, we examined the interactions
between DDX3 and viral proteins in BHK-21cells. We ﬁrst infected
the BHK-21 cells with JEV (MOI¼0.01). 48 h later, the anti-DDX3
polyclonal antibody was used to co-immunoprecipitate the pro-
teins from the whole cell lysate. The results showed JEV NS3 and
NS5 proteins could be co-immunoprecipitated by the endogenous
DDX3 (Fig. 5C). Since DDX3 is a nucleic acid-binding protein, it is
possible that the interactions might be mediated by RNA or DNA,
and then we determined the interactions between DDX3 and
viral proteins in the presence of RNase (100 μg/ml) and DNase
(100 μg/ml). Western blot analysis showed that the interaction
between DDX3 and JEV NS3 or NS5 proteins was not mediated by
RNA or DNA (Fig. 5D).
Several studies reported that DDX3 can be incorporated into
HBV, Herpes simplex virus type 1(HSV-1) and Human cytomega-
lovirus (HCMV) (Stegen et al., 2013; Varnum et al., 2004; Wang
et al., 2009), so we also determined whether DDX3 was incorpo-
rated into the JEV virions. We infected the BHK-21 cells with JEV
(MOI¼0.01) for 48 h, the anti-E monoclonal antibody was used to
co-immunoprecipitate the mature virions in the medium, the
virions were then detected using anti-DDX3 polyclonal antibody
by western blot analysis. We did not detect the presence of DDX3
in our experiment, suggesting that DDX3 is not incorporated into
the JEV virions (Fig. 5E).
DDX3 colocalized with the JEV NS3 and NS5 proteins and viral RNA
during virus infection
As previously reported, DDX3 is primarily localized in the cyto-
plasm (Choi and Lee, 2012; Lai et al., 2008). To ﬁnd out whether
Fig. 3. The effect of exogenous DDX3 and helicase-dead DDX3s on JEV replication. (A) BHK-21 cells were ﬁrst transfected with DDX3 shRNA plasmid (DDX3i). 24 h later, the
cells were transfected with either pcDNA3.1-DDX3-HA, pcDNA3.1-DDX3r-K230E-HA, pcDNA3.1-DDX3r-S382L-HA or pcDNA3.1 plasmid. The viral titers were determined by
plaque formation assay at 48 hpi (MOI¼0.01). (B) The levels of JEV genome RNAwere detected by real-time PCR in JEV-infected cells after the cells were ﬁrst transfected with
the DDX3i plasmid before pcDNA3.1-DDX3r-HA, pcDNA3.1-DDX3r-K230E-HA or pcDNA3.1-DDX3r-S382L-HA plasmid transfection, the control shRNA and pcDNA3.1 plasmid
were used as the control. (C) The expression of DDX3 mutant plasmids and the endogenous DDX3 were detected by Western blot using anti-HA monoclonal antibody and
anti-DDX3 polyclonal antibody. The β-actin was used as the loading control. (D) The cell viability of BHK-21 cells transfected with either DDX3-shRNA, control-shRNA, DDX3-
shRNA/pcDNA3.1-DDX3r, DDX3-shRNA/pcDNA3.1-DDX3r-K230E-HA, DDX3-shRNA/pcDNA3.1-DDX3r-S382L –HA, DDX3-shRNA /pcDNA3.1 or control shRNA/pcDNA3.1 was
detected by CytoTox 96s NonRadioactive Cytotoxicity Assay (Promega) at 72 h after transfection. The differences between means were considered signiﬁcant at *po0.05,
very signiﬁcant **po0.01.
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the cellular localization of the endogenous DDX3 was changed
during JEV infection and whether DDX3 colocalized with JEV NS3
and NS5 proteins, we infected BHK-21 cells with JEV (MOI¼0.01)
for 48 h, and studied the localization of DDX3 and viral proteins by
confocal microscopy. The results demonstrated that DDX3 coloca-
lized with JEV NS3 and NS5 proteins in the cytoplasm (Fig. 6A). We
did not observe any changes in the distribution of DDX3 in the
cells infected with JEV (MOI¼0.01) compared with mock-infected
cells. The monoclonal antibody against JEV envelope protein was
used to conﬁrm that the cells were not infected. Meanwhile, we
also found that endogenous DDX3 colocalized with JEV RNA in the
cytoplasm (Fig. 6B), implying that DDX3 might be involved in JEV
RNA replication.
DDX3 interacts with JEV 5′ and 3′ UTR and positively regulate JEV
protein translation and viral RNA replication
Since JEV NS3 and NS5 bind to the 3′ UTR of the viral RNA
during virus replication (Chen et al., 1997), we next determined
whether DDX3 could bind to JEV 5′or/and 3′–UTR. We labeled JEV
5′ and 3′ UTR with Tobramycin Afﬁnity Tag to enable the RNAs to
bind to tobramycin matrix beads to pulldown the endogenous
DDX3. The Western blot results showed that DDX3 could bind to
both JEV 5′ and 3′ UTRs (Fig. 7A), which was consistent with the
fact that DDX3 colocalized with viral RNA during the infection
(Fig. 6B).
It has been suggested that 5′ and 3′ UTR of JEV are both
involved in the ﬁrst round of viral protein translation and also in
the virus RNA replication (Chien et al., 2011), so we constructed a
JEV replicon reporter system to determine whether DDX3 could
regulate viral translation and/or RNA replication according to the
previous study (Chien et al., 2011). BHK-21 cells were ﬁrst
transfected with DDX3 shRNA to knockdown the expression of
DDX3, the non-targeting shRNA was used as the control. The cells
were then transfected with in vitro-transcribed JEV replicon and
ﬁreﬂy luciferase RNA was used as the internal control. The cells
were harvested for dual luciferase assays at 3, 6, 9, 24, 48, and 72 h
post transfection. The results showed that there were two peaks of
replicon luciferase activity, which represented the ﬁrst translation
and the second replication peak. In DDX3 knockdown cells, lower
luciferase activities were observed for all of the time points in both
peaks (Fig. 7B), indicating that viral protein translation and viral
RNA replication were all hampered by the knockdown of DDX3.
Because JEV RNA replication depends on viral proteins, we next
conﬁrmed the roles of DDX3 on viral translation using a
replication-deﬁcient replicon, which contains a GDD-AAG muta-
tion in NS5 polymerase (Blight et al., 2003). The results showed
that luciferase activity derived from deﬁcient-replicon RNA was
lower in DDX3 knockdown cells when compared with the control
cells (Fig. 7C). However, the luciferase activities derived from a
control reporter, Renilla luciferase ﬂanked by cellular GAPDH 5′
and 3′ UTRs were not signiﬁcantly changed (Fig. 7D). In conclusion,
all the data demonstrated that DDX3 could positively regulate JEV
infection by promoting viral protein translation. Because DDX3 can
bind to viral 3′ UTR and viral NS3 and NS5 proteins, DDX3 might
promote viral RNA replication.
Discussion
The prevalence of the disease caused by JEV and the limited
efﬁcacy of therapies stimulate the search for safer and more
effective antiviral agents against JEV infection. Recently, new
compounds have been discovered to inhibit JEV replication by
targeting the virus (Chen et al., 1997; Chien et al., 2008; Deas et al.,
2005; Ishag et al., 2013a, 2013b; Lee et al., 2011; Li et al., 2012;
Nawa et al., 2003; Ray and Shi, 2006; Yoo et al., 2009). However,
the virus resistance to these kinds of inhibitors has been a
problem. One possible solution to overcome virus resistance
mutations is to target host cellular factors (Garbelli et al., 2011).
Theoretically, a drug targeting the cellular factors important for
the viral life cycle can be used to inhibit the viral infection (Kwong
et al., 2005). Various host proteins are known to interact with
DDX3, such as several translation initiation factors, transcription
factor SP1, spliced mRNA in an exon junction complex, mRNP
complex, nucleo-cytoplasmic shuttling proteins (CRM1 and TAP)
(Garbelli et al., 2011; Lai et al., 2008; Schröder, 2010; Yennamalli
et al., 2009) and eIF4E(Shih et al., 2007). Several viral proteins have
also been reported to interact with DDX3, including hepatitis B
virus DNA polymerase, hepatitis C virus core protein, vaccinia virus
K7, HIV-1 and poxviruses proteins (Angus et al., 2010; Ariumi et al.,
2007; Mamiya and Worman, 1999; Owsianka and Patel, 1999;
Schröder, 2010; Sun et al., 2010; Wang et al., 2009; Wang and
Ryu, 2010). Given that DDX3 is required for replication of HBV, HCV,
Fig. 4. The effect of the helicase activity of DDX3 on JEV infection. (A) BHK-21 cells
were infected with JEV (MOI¼0.01), then Cmp6 at different concentrations
(0–50 μM) was added. The amount of virus released into the medium was
determined by plaque formation assay at 48 hpi. (B) The JEV genomic RNA levels
in JEV infected BHK-21 cells treated with Cmp6 of different concentrations were
monitored by Q-PCR. (C) The Cytotoxicity of Cmp6 on BHK-21 cells was detected by
CytoTox 96s NonRadioactive Cytotoxicity Assay at 48 h after added to the cells with
different the concentrations (0–200 μM). The differences between means were
considered signiﬁcant at *po0.05, very signiﬁcant **po0.01.
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HIV and poxviruses, it can be suggested that it is a promising target
for drug development against these viruses that pose major global
health threats (Garbelli et al., 2011; Kwong et al., 2005).
Many single-stranded positive-sense RNA viruses have been
reported to use the host intracellular membranes as platforms for
viral replication (Strauss and Strauss, 1994; Wimmer et al., 1993).
The viral genome replication is thought to utilize viral proteins as
well as host proteins (Kuo et al., 1996; Lindenbach et al., 2005;
Lindenbach and Rice, 1997; Mackenzie et al., 1998; Uchil and
Satchidanandam, 2003; Westaway et al., 1997). In our studies, we
demonstrated that DDX3 was required for JEV replication, the
infectious virus production was strongly inhibited by DDX3 knock-
down. We also conﬁrmed that helicase activity of DDX3 was
crucial for JEV replication.
It has been predicted that JEV 5′ and 3′ UTR contain highly
conserved RNA secondary structures involved in the regulation of
viral translation and RNA replication (Brinton and Dispoto, 1988;
Song et al., 2008). The minus-strand RNA synthesis requires the
presence of both the 5′ and 3′ UTR (You et al., 2001), and genomic
RNA cyclization mediated by 5′ and 3′–UTR is essential for viral
replication in all mosquito-borne ﬂaviviruses (Fan et al., 2011;
Ivanyi-Nagy and Darlix, 2012). DDX3 also has been reported to be
involved in translation initiation (Geissler et al., 2012) and DDX3
can promote HIV proteins translation by binding to viral 5′ UTR. It
is most likely that DDX3 destabilizes the RNA structure locally to
form a region large enough to allow the recognition of the m7GTP
cap or loading onto the 40S subunit to initiate protein translation
(Soto-Rifo et al., 2012). A recently published paper suggests that
HCV 3′ UTR retains ribosome complexes during translation termi-
nation to facilitate efﬁcient initiation of subsequent rounds of
translation (Bai et al., 2013). Our JEV replicon experiment con-
ﬁrmed that DDX3 positively regulates JEV protein translation.
JEV NS3 and NS5 proteins have been shown to play important
roles in viral genome replication (Chen et al., 1997). Although we
conﬁrmed the role of DDX3 in JEV protein translation, we could
not rule out its role in viral RNA replication in our studies. Since
DDX3 could bind to JEV 5′ and 3′ UTR and the helicase activity was
necessary for JEV replication, we suspected that DDX3 might help
the unwinding of the secondary structure viral RNA to enable viral
RNA replication more efﬁciently; especially our GST-pulldown,
Fig. 5. DDX3 interacts with JEV NS3, NS5-MTase and NS5-RdRp. (A) In vitro interaction analyses of DDX3 with JEV NS3, NS5-MTase and NS5-RdRp using GST-pulldown
experiment. GST-fused JEV, NS3, NS5-MTase or NS5-RdRp protein was ﬁrst incubated with GST beads. After washing ﬁve times with PBS, the beads were incubated with
His-tagged DDX3. The target proteins were detected by anti-His or anti-GST monoclonal antibody. (B) GST-fused DDX3 was incubated with GST beads ﬁrst. The beads were
then incubated with either His-tagged JEV NS3, NS5-MTase or NS5-RdRp protein after extensive washing with PBS. The target proteins were detected by Western blot
analysis using anti-His or anti-GST monoclonal antibody. The GST protein was used as the control. (C) DDX3 interacted with JEV NS3, NS5 proteins during virus infection.
BHK-21 cells was infected with JEV (MOI¼0.01). 48 h later, the anti-DDX3 polyclonal antibody was used to co-immunoprecipitate proteins from the whole cell lysate either
in the absence or presence of RNase (100 μg/ml) and DNase (100 μg/ml). The JEV-NS3 and NS5 proteins were detected using their polyclonal antibodies respectively. The cell
lysates (2% input) were analyzed in parallel by western blot. (D) DDX3 was not incorporated into the virions. BHK-21 cells were infected with JEV (MOI¼0.01) for 48 h, the
anti-E monoclonal antibody was used to immunoprecipitate the mature virions in the medium, the proteins in the immunoprecipitated virions (IP) were detected with anti-
DDX3, anti-envelope (E protein) or anti-core protein antibody.
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Fig. 6. The colocalization analysis of endogenous DDX3, JEV NS3, NS5 proteins and viral RNA. (A) The location of endogenous DDX3 in JEV infected BHK-21 cells and the colocalization
of DDX3 with JEV NS3 and NS5 proteins. BHK-21 cells were infected with JEV (MOI¼0.01), 48 h later, DDX3, JEV NS3 and NS5 proteins were detected using their polyclonal antibodies
and the colocalization study was performed under confocal microscopy. (B) The colocalization of DDX3 and viral RNA. BHK-21 cells were infected with JEV (MOI¼0.01), endogenous
DDX3 was detected by anti-DDX3 polyclonal antibody and the viral RNA was detected (red) using the Click-iTs RNA Imaging Kit at 24 hpi under confocal microscopy. The mock-
infected cells were also included as a control.
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co-immunoprecipitation and confocal microscopy analyses
demonstrated that DDX3 could interact with JEV NS3, NS5 and
viral RNA.
Collectively, our results suggested that DDX3 regulates JEV
replication by modulating JEV protein expression. Therefore, the
drugs targeting DDX3 might be used for treatment of Japanese
encephalitis virus or other ﬂaviviruses infection.
Materials and methods
Viruses, cells and transfection
BHK-21 cells (C-13, American Type Culture Collection) were
maintained in Dulbecco's minimal essential medium supplemen-
ted with 10% fetal bovine serum and penicillin (100 U/ml) and
streptomycin (100 mg/ml) at 37 1C in 5% CO2. SA14-14-2 strain of
JEV was propagated in BHK-21 cells, and the viral titers were
determined by plaque formation assay. The cells were transfected
using polyethylenimine (25 kDa; Sigma-Aldrich). The amount of
plasmid DNA with which the cells were transfected (1 μg per well
of 24-well plate and 10 μg per 100 mm plate) was kept constant by
the inclusion of empty expression vector. Transfection efﬁciencies
around 70% were routinely obtained by using pEGFP-N2 (Clontech)
plasmid to monitor the transfection efﬁciency.
Plasmids and RNA interference
To construct HA-tagged pcDNA3.1-DDX3, pGEX-4T-3-DDX3, pCold-
I-DDX3, and DDX3 gene were ampliﬁed by PCR using HA-DDX3
plasmid (as a gift from Prof. K.T. Jeang) as the template with speci-
ﬁc primers and cloned into pcDNA3.1-(þ) (Invitrogen), pGEX-4T-3
(GE Healthcare) or pCold-I (Takara) vector respectively. The genes
encoding JEV core, NS3, NS5-MTase (1–268) or NS5-RdRp (318–905)
were also subcloned into pET-24a (þ) vector (Novagen).
The Oligonucleotides GTGCCGTCTTGGTTAGAAA was cloned into
pGPU6/Neo vector as short hairpin RNA (shRNA) plasmid against
DDX3 (Lai et al., 2008). The oligodeoxyribonucleotide encoding non-
targeting shRNA (GTTCTCCGAACGTGTCACGT) was cloned into pGPU6/
Neo vector by Genepharma (Shanghai, China), which was used as the
negative control. PcDNA3.1-DDX3-K230E-HA, pcDNA3.1-DDX3-S382L-
HA mutants were made with Quick-Change site-directed mutagenesis
kit (Stratagene) according to the manufacturer's instructions using
pcDNA3.1-DDX3-HA as the template by PCR using speciﬁc primers. To
construct RNA interference resistant pcDNA3.1-DDX3r, pcDNA3.1-
DDX3r-K230E-HA or pcDNA3.1-DDX3r-S382L-HA mutant plasmid,
the correspondent sequence to DDX3 shRNA in these DDX3 mutants
was mutated into GTCCCATCATGGCTGGAG without introducing any
residue change by using QuikChange site-directed mutagenesis kit
(Stratagene) using pcDNA3.1-DDX3-HA, pcDNA3.1-DDX3-K230E-HA
or pcDNA3.1-DDX3-S382L-HA as the template. The nucleotide sequen-
ces of all the plasmids were conﬁrmed by DNA sequencing.
To construct the templates for JEV 5′ and 3′ UTR RNA transcription,
the JEV 5′ or 3′ UTR gene was ampliﬁed by PCR with speciﬁc primers:
JEV5′-sense primer: TAATACGACTCACTATAGGGAGAAGTTTATCTGTGT-
GAACTTCTTGGCTTAG, anti-sense primer: GGCTCAGCACGAGTGTAGC-
TAAACCTCGCTATACT AAGCCGGTTATCTTCCGTTCTAA, JEV 3′-sense
primer: TAATACGACTCA TAGGGTAGTGTGATTTAAGGTAGAAAAGTAG,
JEV 3′anti-sense:GGCTCA GCACGAGTGTAGCTAAACCTCGCTATACTAA-
GCCAGATCTTGTGTTCTTCCT. An unrelated control RNA was gene-
rated by PCR ampliﬁcation of part of the ampicillin resistance gene
from pcDNA3.1 (þ) vector (1–250 bp) using ampicillin-sense
Fig. 7. DDX3 bound to JEV 5′ and 3′-UTR and modulated JEV protein translation and RNA replication. (A) DDX3 bound to JEV 5′ and 3′-UTR. JEV 5′ and 3′-UTR or the control
RNA was transcribed in vitro, then incubated with tobramycin conjugated matrix beads. The beads were then incubated with BHK-21 cell lysate. DDX3 was detected by
Western blot using anti-DDX3 polyclonal antibody. (B) BHK-21 cells were co-transfected with a Renilla luciferase JEV replicon, a Renilla luciferase JEV-replication deﬁcient
replicon (C) and a Renilla luciferase reporter ﬂanked by GAPDH 5′ and 3′ UTRs plus ﬁreﬂy luciferase RNA (D) as the control. At various time points post transfection, cell
lysates were collected for dual-luciferase assays. Renilla luciferase activity was normalized to that of ﬁreﬂy luciferase. The differences between means were considered
signiﬁcant at *po0.05, very signiﬁcant **po0.01.
C. Li et al. / Virology 449 (2014) 70–81 77
primer: TAATACGACTCACTATAGGGATGAGTATTCAACATT TCCGTG-
TCG and ampicillin-anti-sense primer: GGCTCAGCAC GAGTGT-
AGCTAAACCTCGCTATACTAAGCCCGTCAATACGGGATAATAC (Vashist
et al., 2012). T7 promoter and tobramycin aptamer tag (Hartmuth
et al., 2004) sequences underlined were included in sense and anti-
sense primer respectively. The PCR products were subcloned into
pMD-18T vector (Takara, China). The nucleotide sequences of all
the constructs were conﬁrmed by DNA sequencing.
The JEV replicon with Renilla luciferase gene was generated by
cloning JEV SA14-14-2 strain cDNA into pBluescript II KS (Agilent
Technologies) under the control of a T7 promoter as the previous
study (Chien et al., 2011). The Renilla luciferase gene was inserted
after the ﬁrst 102 bp of the JEV C gene, followed by the foot-and-
mouth disease virus 2A self-cleaving protease (FMDV-2A) to
enable the cleavage of the luciferase away from downstream
nonstructural proteins (Lo et al., 2003; Varnavski and Khromykh,
1999). FMDV 2A was fused to the last 90 bp of the E gene that is
necessary for the proper topology of the following viral proteins.
To ensure RNA stability and processing, a hepatitis delta virus
ribozyme was placed immediately adjacent to the 3′ end of the JEV
cDNA followed by a bovine growth hormone (BGH) polyadenyla-
tion sequence. The JEV-replication-deﬁcient replicon was con-
structed by introducing a mutation (GDD-AAG) in NS5 gene
(Blight et al., 2003) using Quick-Change site-directed mutagenesis
kit (Stratagene) with the speciﬁc primers. The control construct:
GAPDH 5′ and 3′UTR-ﬂanking luciferase reporter gene, was cloned
into pMD-18T Vector (Takara, China).
Protein expression and puriﬁcation
To express the proteins used in the experiments, the plasmid
pCold-I-DDX3, pGEX-4T-3-DDX3, pET-24a (þ)-core, pET-24a (þ)–
NS3, pET-24a (þ)-NS5-MTase, pET-24a (þ)–NS5- RdRp, pGEX-4T-
3-NS3, pGEX-4T-3-NS5-MTase or pGEX-4T-3-NS5-RdRp was trans-
formed into E. coli expression strain Rosetta 2 cells. A single colony
was used to inoculate 10 ml of Luria-Bertani (LB) media containing
either ampicillin (100 μg/ml) or kanamycin (50 μg/ml), and the
culture was grown at 37 1C overnight. The cultures were then
diluted into the LB media containing either ampicillin (100 μg/ml)
or kanamycin (50 μg/ml) and grown to an A600 of 0.6 at 37 1C;
protein expression was then induced with 0.1 mM IPTG for
16–20 h at 22 1C. The cells were harvested by centrifugation at
5000g for 20 min at 4 1C and re-suspended in lysis buffer (100 mM
NaCl, 20 mM Tris–HCl, pH 8.0, 0.1 mM PMSF). The cells were
disrupted by sonication, and the supernatant was collected by
centrifugation. The supernatant was then subjected to afﬁnity
puriﬁcation using Bio-Rad Proﬁnity™ IMAC or Proﬁnity™ GST
column (Bio-Rad). The proteins were then eluted, pooled together
and further puriﬁed using size exclusion chromatography (Super-
dex75, GE Healthcare). The concentration of the puriﬁed protein
was determined by Bradford assay.
Antibodies
The DDX3 rabbit polyclonal antibody, anti-β-actin, anti-GST,
anti-His monoclonal antibodies and HRP conjugated secondary
antibody were purchased from Abmart Company (Shanghai,
China). The monoclonal antibody against the JEV envelope glyco-
protein was described previously (Ishag et al., 2013b). To produce
anti-core, NS3 and NS5 polyclonal antibodies of mice source, the
BALB/c mice free of pathogens was inoculated with 50 mg of NS5-
RdRp protein emulsiﬁed with equal amount of Freund's complete
adjuvant (Sigma-Aldrich) via subcutaneous injection. Booster
doses were subsequently given at 1, 2 and 3 weeks later with
50 mg of NS3, NS5-RdRp emulsiﬁed with incomplete adjuvant.
Finally, the serum of the mice was collected. The serum of the mice
without immunized with any protein was collected as the negative
serum. Both immunoblot and ELISA were performed to evaluate
the immunoreactivity between JEV NS3 and NS5 proteins and their
polyclonal antibodies. Animal use was in compliance with the
Nanjing Agricultural University Institutional Animal Care and Use
Committee.
Plaque formation assay
The viral culture supernatants with 10-fold dilutions (from 102
to 105) were added into 6-well plate with conﬂuent monolayer of
BHK-21. The plate was then incubated at 37 1C for 2 h, with gentle
agitation at every 15-min interval. The excess virus inocula were
removed by rinsing the cells with PBS for three times. Subse-
quently, overlay medium (2% low melting-point agarose with
DMEM medium containing 2% FBS) was added to each well and
further incubated at 37 1C with 5% CO2 for 3–5 days. The cells were
stained with 0.5% crystal violet.
Cytotoxicity assay
The cell viability of BHK-21 cells transfected with the plasmids
was detected by the lactate dehydrogenase (LDH) activity, a stable
cytosolic enzyme that is released upon cell lysis using CytoTox 96s
NonRadioactive Cytotoxicity Assay (Promega) at 72 h after trans-
fection. The Cytotoxicity of cmp6 on BHK-21 cells was detected by
CytoTox 96s NonRadioactive Cytotoxicity Assay at 48 h after being
added to the cells with different the concentrations (0–200 ng/ml).
GST pulldown assay
50 μl glutathione-Sepharose 4B beads (GE Healthcare) were
resuspended in binding buffer (20 mM Tris–HCl, pH 7.5, 500 mM
NaCl, 0.5% NP-40, and 0.1 mM PMSF). 10 mg puriﬁed GST-DDX3,
GST-NS3, GST-NS5-MTase or GST-NS5-RdRp was incubated with
the beads for 2 h at 4 1C under gentle agitation. Unbounded
proteins were washed away using washing buffer (20 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 0.1% NP-40, 0.1 mM PMSF). The puriﬁed
NS3, NS5-MTase, NS5-RdRp or DDX3 protein was incubated with
the beads overnight with gentle agitation at 4 1C respectively. The
beads were washed four times with 1 ml of washing buffer. Finally
the beads were resuspended in 200 ml of SDS-PAGE sample buffer
and boiled. 15 μl protein sample was separated on 12% or 15% SDS-
PAGE gel and then transferred to PVDF membrane. The presence of
the targeted protein was detected with either anti-DDX3 poly-
clonal antibody or anti-His monoclonal antibody. Glutathione-
Sepharose 4B beads incubated with GST proteins were used as
control.
Co-immunoprecipitation assay
BHK-21 cells were infected with JEV for 48 h. The cells were
rinsed twice in cold phosphate-buffered saline and incubated for
3 h at 4 1C in lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl,
1 mM EDTA, 1 mM dithiothreitol, 0.2 mM PMSF, 1% NP-40) with
gentle agitation. Cell debris was removed by centrifugation at
10,000g for 10 min at 4 1C. The protein A/G (Abmart) agarose
beads coupled with DDX3 polyclonal antibody were incubated
with the supernatant either in the absence or presence of RNase
(100 μg/ml) and DNase (100 μg/ml) for 2 h at 4 1C. The beads were
washed ﬁve times with 1 ml washing buffer (20 mM Tris–HCl, pH
7.5, 150 mM NaCl, 0.1% NP-40), resuspended in 200 ml SDS-PAGE
sample buffer and boiled. The protein samples were then sub-
jected to Western blot analysis. The targeted proteins were
analyzed by western blot analysis using anti-DDX3, anti-NS3 or
anti-NS5 polyclonal antibody.
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Western blot analysis and Q-PCR analysis
The protein mixtures were separated on 12% or 15% SDS-PAGE
gel and transferred to PVDF membrane (Millipore, USA) in a Trans-
Blot SD semidry transfer cell (Bio-Rad, USA). The membrane was
blocked with 5% non-fat milk powder in TBST buffer (20 mM Tris–
HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20), and then probed with
anti-JEV-envelope monoclonal antibody, anti-β-actin antibody the
bound antibody was detected using HRP-conjugated secondary
antibody and visualized using enhanced chemiluminescence (GE
Healthcare). The intensity band ratio of grayscale for JEV envelope,
NS5 and DDX3 proteins were analyzed by ImageJ software using
β-actin as the internal control.
JEV-speciﬁc RNA copy number was quantiﬁed using quantita-
tive PCR (Q-PCR). The total RNA was extracted from JEV-infected
BHK-21 cells with TRIzol reagent (Invitrogen), and puriﬁed accord-
ing to the Manufacturer's recommendations. For cDNA prepara-
tion, total RNA (1 mg) was reverse transcribed with ﬁrst strand
cDNA synthesis kit (Takara, China). cDNA samples were ampliﬁed
with the RT-PCR kit. Intracellular JEV genome levels were quanti-
ﬁed with the SYBR Green Probe 3-step Q-PCR kit (Takara, China)
and ﬂuorescent quantization machine (ABI PRISM 7300 sequence
detection system, Applied Biosystems). The primer for the JEV NS1
and β-actin were the following: NS1 sense primer: 5′-acactcgtca-
gatcacaggttca-3′; antisense primer: 5′-gccagaaacatcaccagaagg-3′,
β-actin sense primer: 5′catccgtaaagacctctatgccaac-3′, antisense
primer, 5′-atggagccaccgatccaca-3′ and cellular β-actin mRNA from
the same RNA extract was used as an internal control in BHK-21
cells as the previous study (Ishag et al., 2013b).
In vitro RNA transcription and the interaction of JEV 5′ and 3′ UTR
with DDX3
To synthesize RNA in vitro, puriﬁed plasmid was ﬁrst linearized
with BamHI or KpnI enzyme. In vitro transcription of JEV replicon,
replication-deﬁcient replicon, GAPDH-luciferase, JEV 5′, 3′ UTR
and control RNAs were performed using Riboprobes System-T7
Kit (Promega, China) in a 20 ml reaction mixture containing 4 ml
5 transcription buffer, 2 ml RNasins RNA Inhibitor (40 U/μl), 1 ml
each NTP (10 mM), 1 μg of linearized DNA template and 1 ml T7
RNA polymerase (20 U/μl). The mixture was incubated at 37 1C for
2 h. 10 ml of DNaseI (1 U/ul) was added to the mixture and
incubated at 37 1C for 30 min. The synthesized RNAs were puriﬁed
using the RNeasy mini kit (Qiagen) and analyzed by 1% agarose
gels. JEV 5′, 3′ UTR and control RNAs were added to the matrix
beads conjugated with tobramycin (Hartmuth et al., 2004) and
incubated by head-over-tail rotation for 1–1.5 h. The matrix beads
were washed three times with PBS (prepared with 0.1% diethyl
pyrocarbonate-treated water). The supernatants of BHK-21 cell lysate
were mixed with beads and incubated by head-over-tail rotation for
2 h. The mixture was subjected to Western blot analysis using anti-
DDX3 polyclonal antibody. The JEV 5′ and 3′ UTR RNA were detected
on 1% agarose and stained with ethidium bromide (EB).
Confocal microscopy analysis
BHK-21 cells were plated onto cover slips in a 6-well plate. In
the following day, the cells were infected with JEV. 48 h later, the
cells were ﬁxed with ethanol for 30 min at 4 1C. Viral proteins and
endogenous DDX3 were ﬁrstly stained with their polyclonal
antibodies. The cells were then washed with PBS and treated for
60 min at room temperature with Rhodamine-conjugated or FITC-
conjugated secondary antibody (Invitrogen, China). The coverslip
was mounted onto the slide glass using PBS containing 50%
glycerol. The cell nucleus was stained using 4′,6-diamidino-2-
phenylindole (DAPI) (Sigma, China). For viral RNA staining, cells
were ﬁrst infected with JEV (MOI¼0.01). 3 h later, the cells were
treated with actinomycin D (Sigma, China) for 4 h (15 mg/ml) (Xu
et al., 2010) to inhibit cellular RNA transcription before 5-ethynyl
uridine (EU) was supplied. The viral RNA was detected using
the Click-iTs RNA Imaging Kits (Invitrogen, China) according to
the manufacturer's instructions. The coverslip was mounted onto
the slide glass using PBS containing 50% glycerol. The cell nucleus
were stained using 4′,6-diamidino-2-phenylindole (DAPI) (Sigma,
China). Confocal images were obtained using a Zeiss LSM 710
scanning confocal microscope.
Luciferase reporter assay
For the replicon luciferase reporter assay, BHK-21 cells were
seeded in 24-well plates and transfected with DDX3 shRNA plas-
mid. 24 h later, the cells were transfected with 0.6 mg in vitro-
transcribed JEV replicon RNA plus 0.2 mg of a ﬁreﬂy luciferase RNA
in vitro-transcribed as an internal control using TransFast™
(Promega). At the indicated time points post transfection, cell
lysates were collected for the dual-luciferase assay using Dual-
Luciferases Reporter Assay System Kit and GloMaxs 20/20 Lumi-
nometer instrumentation (Promega).
Statistical analysis
All data were determined in triplicate and were representative
of at least two separate experiments. The results represented the
means7standard deviations of triplicate determinations. The
differences between means were considered signiﬁcant at
npo0.05 and very signiﬁcant nnpo0.01. All statistical analyses
were performed by one-way ANOVA using a SPSS 16.0 software
package (version 16.0, SPSS Inc., Chicago, IL, USA).
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